Drug intelligence / Profile preview

CTL-0901

Development stage: Unknown
Lead developer: Celltrion
Modality: Small Molecules
Administration: Oral

Overview

CTL-0901 is an investigational **small molecule drug** developed by Celltrion, Inc. It has been evaluated in a completed Phase 1 clinical trial to study its pharmacokinetic interaction and safety profile, specifically in a drug-drug interaction study with CTL0902 among healthy adult volunteers. No specific mechanism of action, therapeutic indication, or molecular target has been disclosed publicly. No FDA or EMA approvals or active indications are reported as of the current date[1][3][4][7].

Other names: CTL0901CTL-0901CTL 0901

Beyond the preview

Go deeper on CTL-0901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTL-0901.

Explore the full profile